Dr Reddy's Laboratories announces the launch of a generic version of Sapropterin Dihydrochloride Tablets for Oral Use in the US Market
Hyderabad, India and Princeton, NJ, USA. October 3, 2020 - Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.
“We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease. We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website.”
Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.
“We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease. We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website.”
Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.